RxDoctor Payments Data

Michael Osswald

Hematology & Oncology · Lackland A F B, TXNPI 1467565911

Payments from drug & device makers

$506,792in general payments, 2019–2025

Across 65 payments — averaging $7796.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acerta Pharma LLC$252K
  • Astrazeneca UK Limited$89K
  • Bristol Myers Squibb$79K
  • E.r. Squibb & Sons, L.L.C.$45K
  • Eli Lilly$22K
  • Genmab A/s$15K
  • plus $5K from 2 others
$1,652in research payments, 2019–2025

Across 2 payments — averaging $825.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Food & beverage$121100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$506,792 in reported general payments places this provider in the 80th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Other hematology & oncology in Lackland A F B

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →